A Problem?

Discussion in 'Valeant Pharmaceuticals' started by anonymous, Apr 12, 2020 at 12:43 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    BHC’s stock performance from January 1, 2017 – December 31, 2019

    The stock price for BHC on January 1, 2017 was $13.78/share.

    The stock price for BHC on December 31, 2019 was $29.92/share.

    From January 1, 2017 through December 31, 2019 the stock price increased by $16.14/share.

    Revenue and Net Income for BHC: 2017, 2018, and 2019

    In 2019, BHC generated revenue of approximately 8.6 billion and net income resulted in a net loss of approximately 1.8 billion.

    In 2018, BHC generated revenue of approximately 8.3 billion and net income resulted in a net loss of approximately 4.1 billion.

    In 2017, BHC generated revenue of approximately 8.7 billion and net income resulted in a net gain of approximately 2.4 billion.

    From 2017 through 2019, BHC generated revenue of approximately 25.6 billion and net income resulted in a net loss of approximately 3.5 billion.

    Debt and Net Income for BHC: 2017, 2018, and 2019

    In 2019, BHC had debt of approximately 26 billion and net income of approximately negative 1.8 billion.

    In 2018, BHC had debt of approximately 24 billion and net income of approximately negative 4.1 billion.

    In 2017, BHC had debt of approximately 25 billion and net income of approximately 2.4 billion.

    From 2017 through 2019, BHC’s debt rose by approximately 1 billion and net income of approximately negative 3.5 billion.

    As of April 9, 2020, the stock price for BHC was $18.01/share, which reflects an increase of $4.23/share from January 1, 2017.

    Does a problem exist with anything or everything pertaining to BHC and or Wall Street?
     

  2. anonymous

    anonymous Guest

    Total Contractual Obligations for BHC 2020 – 2024 and Thereafter

    Total long-term debt obligations (including interest) + operating lease obligations + purchase obligations total approximately 36.8 billion from 2020 - Thereafter.
     
  3. anonymous

    anonymous Guest

    What does Joe Papa's compensation look like from 2017 - 2019? Does he deserve what he is being paid?
     
  4. anonymous

    anonymous Guest

    Was BHC better off on December 31, 2019 versus January 1, 2017? If yes, was BHC $16.14/share better off?
     
  5. anonymous

    anonymous Guest

    Your opinion(s) mean nothing no matter how smart your mommy tells you, you are!
     
  6. anonymous

    anonymous Guest

    My mommy doesn't tell me that I'm smart. I haven't shared any of my opinion(s). I'm trying to understand the relationship between stock price, debt, revenue, and net income. What other factors am I not considering?
     
  7. anonymous

    anonymous Guest

    Should I also be considering total assets and debt?

    Total assets and debt:

    2019 total assets for BHC = approximately 34 billion.
    2019 total debt for BHC= approximately 26 billion.

    2018 total assets for BHC = approximately 33 billion.
    2018 total debt for BHC = approximately 24 billion.

    2017 total assets for BHC = approximately 38 billion.
    2017 total debt for BHC = approximately 25 billion.
     
  8. anonymous

    anonymous Guest

    Who determines the value of an asset? Also, how is the value of the asset determined?
     
  9. anonymous

    anonymous Guest

    Market cap has to play a role? I ask that rhetorically. I want to focus on how the value of the assets are derived. For example, who determined the value of Duobrii and how was its value determined?
     
  10. anonymous

    anonymous Guest

    How would you know if BHC's intangible and goodwill assets are being overstated, understated, or properly valued?
     
  11. anonymous

    anonymous Guest

    In my opinion, if I had any interests in BHC, I would be more than a little concerned (I Heard You Paint Houses) if Actavis and or Sandoz was going to launch a generic version of Xifaxan.
     
  12. anonymous

    anonymous Guest

    You are onto them... call the SEC -asap. Ignore the troll that is trying to get to you - her name is Lainie Keller and she gets paid $250,000 to troll cafepharma because she has no other skills ....
     
  13. anonymous

    anonymous Guest

    Valuing an asset is somewhat subjective. The data I posted comes directly from BHC's 2019 Annual Report and everyone has access to that information. If you want to form any of your own solid conclusions regarding the valuation of BHC's assets, you'd need more information. It appears that PWC formed some conclusions. Do you trust BHC or PWC? I personally don't.

    So, what exactly do I have to report to the SEC? I could report ways to get around the Rifaximin patents, but they probably aren't interested in that information. I'm simply asking questions and sharing some of my personal opinions based on the data that is publicly available. You should review the data that is publicly available, then formulate your own questions, opinions, and or conclusions. If you find something that might be of interest to the SEC, then report it.

    Lastly, I couldn't care less about Lainie Keller, what she has to say, what she is being paid, or what her role is at BHC.
     
  14. anonymous

    anonymous Guest

    Someone or a group of people that can crack this could potentially have a huge pay:

    This is an action for infringement of United States Patent Nos. 7,045,620 (the “’620 patent”); 7,612,199 (the “’199 patent”); 7,902,206 (the “’206 patent”); 7,906,542 (the “’542 patent”); 7,915,275 (the “’275 patent”); 8,158,644 (the “’644 patent”); 8,158,781 (the “’781 patent”); 8,193,196 (the “’196 patent”); 8,309,569 (the “’569 patent”); 8,518,949 (the “’949 patent”); 8,642,573 (the “’573 patent”); 8,741,904 (the “’904 patent”); 8,829,017 (the “’017 patent”); 8,835,452 (the “’452 patent”); 8,853,231 (the “’231 patent”); 8,946,252 (the “’252 patent”); 8,969,398 (the “’398 patent”); 9,271,968 (the “’968 patent”); 9,421,195 (the “’195 patent”); 9,629,828 (the “’9,828 patent”); 10,314,828 (the “’4,828 patent”); 10,335,397 (the “’397 patent”); and 10,456,384 (the “’384 patent”) (collectively, the “Xifaxan® patents”) under the Food and Drug Laws and the Patent Laws of the United States, Titles 21 and 35 of the United States code, respectively. This action involves the 550 mg dosage form of Plaintiffs’ drug product Xifaxan®, indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

    What is relevant? What isn't relevant? Who is NORWICH PHARMACETICALS, INC.; ALVOGEN PB RESEARCH AND DEVELOPMENT LLC,? Is this lawsuit a front by BHC to deter others from attempting to develop a generic of their most prized possession?

    Best wishes! I am hoping for a generic to Xifaxan(R) sooner rather than later.
     
  15. anonymous

    anonymous Guest

    The douchebag above is on a wild ridiculous fishing expedition. You will come back disappointed!
     
  16. anonymous

    anonymous Guest

    Got Em! You didn't comment after the figures from BHC's annual report were posted. However, after I posted Xifaxin's patent litigation, you became defensive yet confident. Why?

    The people that have witnessed me on a ridiculous wild fishing expedition (in response to ridiculously wild claimants) would most likely agree that what I posted above is much different.
     
  17. anonymous

    anonymous Guest

     
  18. anonymous

    anonymous Guest

    Holdontah Deasnus
     
  19. anonymous

    anonymous Guest

    so you admit you are a douchebag! LOLOLOL!!
     
  20. anonymous

    anonymous Guest

    Yes Joe, I'm a douche bag. Everyone thanks you for pointing out the obvious. Jim Cramer is looking for a company that is "pivoting to offense" in 2020, do you know of any? What's this years slogan?

    In 2019, Joe Papa generated a net loss of approximately 1.8 billion.

    In 2018, Joe Papa generated a net loss of approximately 4.1 billion.

    In 2017, Joe Papa generated a net gain of approximately 2.4 billion.

    Outstanding job you're doing! Open up your books and lets see what's REALLY going on!